BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 16279562)

  • 1. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease.
    White AA; Stevenson DD; Simon RA
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):330-5. PubMed ID: 16279562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Clin Exp Allergy; 2002 Oct; 32(10):1491-6. PubMed ID: 12372130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.
    Stevenson DD; Mehra PK; White AA; Gupta S; Woessner KM; Simon RA
    J Allergy Clin Immunol; 2005 Oct; 116(4):755-60. PubMed ID: 16210047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2002 Nov; 89(5):474-8. PubMed ID: 12452205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis.
    Dursun AB; Woessner KA; Simon RA; Karasoy D; Stevenson DD
    Ann Allergy Asthma Immunol; 2008 May; 100(5):420-5. PubMed ID: 18517072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
    White A; Ludington E; Mehra P; Stevenson DD; Simon RA
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):688-93. PubMed ID: 17165280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
    Woessner KM; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges.
    Williams AN; Simon RA; Woessner KM; Stevenson DD
    J Allergy Clin Immunol; 2007 Aug; 120(2):273-7. PubMed ID: 17481713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease.
    White A; Bigby T; Stevenson D
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):190-5. PubMed ID: 16937750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases.
    Katial RK; Strand M; Prasertsuntarasai T; Leung R; Zheng W; Alam R
    J Allergy Clin Immunol; 2010 Oct; 126(4):738-44. PubMed ID: 20728206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
    Fraj J; Valero A; Vives R; Pérez I; Borja J; Izquierdo I; Picado C
    Allergy; 2008 Jan; 63(1):112-5. PubMed ID: 18053020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease.
    Mullol J; Picado C
    Immunol Allergy Clin North Am; 2013 May; 33(2):163-76. PubMed ID: 23639706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2003 Mar; 90(3):338-41. PubMed ID: 12669898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma.
    Mascia K; Haselkorn T; Deniz YM; Miller DP; Bleecker ER; Borish L;
    J Allergy Clin Immunol; 2005 Nov; 116(5):970-5. PubMed ID: 16275362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to nonsteroidal anti-inflammatory drugs.
    Namazy JA; Simon RA
    Ann Allergy Asthma Immunol; 2002 Dec; 89(6):542-50; quiz 550, 605. PubMed ID: 12487218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.
    Lee RU; White AA; Ding D; Dursun AB; Woessner KM; Simon RA; Stevenson DD
    Ann Allergy Asthma Immunol; 2010 Aug; 105(2):130-5. PubMed ID: 20674823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease.
    Hope AP; Woessner KA; Simon RA; Stevenson DD
    J Allergy Clin Immunol; 2009 Feb; 123(2):406-10. PubMed ID: 19056109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper.
    Macy E; Bernstein JA; Castells MC; Gawchik SM; Lee TH; Settipane RA; Simon RA; Wald J; Woessner KM;
    Ann Allergy Asthma Immunol; 2007 Feb; 98(2):172-4. PubMed ID: 17304886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
    Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenomenology, pathogenesis, diagnosis and treatment of aspirin-sensitive rhinosinusitis.
    Schapowal AG; Simon HU; Schmitz-Schumann M
    Acta Otorhinolaryngol Belg; 1995; 49(3):235-50. PubMed ID: 7484142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.